Transfusion under proinflammatory conditions increases the risk of alloimmunization (based on transfusion events)
| Clinical variables . | Alloantibody-positive transfusions, n = 33 events . | Alloantibody-negative transfusions, n = 550 events . | OR (95% CI)∗ . | P value . |
|---|---|---|---|---|
| Proinflammatory events | ||||
| Yes | 20 (60.6%) | 77 (14.0%) | 7.85 (2.98, 20.65) | <.001 |
| No | 13 (39.4%) | 473 (86.0%) | — | — |
| Aplastic crisis | ||||
| Yes | 3 (9.1%) | 1 (0.2%) | 87.86 (2.83, 2727) | .011 |
| No | 30 (90.9%) | 549 (99.8%) | — | — |
| Laboratory tests | ||||
| Hb (g/dL) | 9.10 (∼7.80-10.40) | 9.80 (∼9.10-10.80) | 0.63 (0.43, 0.94) | .023 |
| Absolute reticulocyte count (106/μL)† | 0.26 (∼0.15-0.34) | 0.21 (∼0.17-0.28) | 146.43 (0.01, 2644816) | .317 |
| WBC (103/μL)‡ | 12.40 (∼9.90-16.45) | 10.60 (∼6.90-14.20) | 1.03 (0.94, 1.12) | .517 |
| ANC ((/μL)§ | 7400 (∼5800-8500) | 5748 (∼2800-8200) | 1.01 (0.88, 1.16) | .869 |
| LDH (unit/L) | 495 (∼409-653) | 460 (∼367-544) | 1.29 (0.94, 1.79) | .118 |
| Total bilirubin (mg/dL) | 3.50 (∼1.50-5.50) | 2.80 (∼1.60-3.80) | 1.01 (0.73, 1.40) | .951 |
| Clinical variables . | Alloantibody-positive transfusions, n = 33 events . | Alloantibody-negative transfusions, n = 550 events . | OR (95% CI)∗ . | P value . |
|---|---|---|---|---|
| Proinflammatory events | ||||
| Yes | 20 (60.6%) | 77 (14.0%) | 7.85 (2.98, 20.65) | <.001 |
| No | 13 (39.4%) | 473 (86.0%) | — | — |
| Aplastic crisis | ||||
| Yes | 3 (9.1%) | 1 (0.2%) | 87.86 (2.83, 2727) | .011 |
| No | 30 (90.9%) | 549 (99.8%) | — | — |
| Laboratory tests | ||||
| Hb (g/dL) | 9.10 (∼7.80-10.40) | 9.80 (∼9.10-10.80) | 0.63 (0.43, 0.94) | .023 |
| Absolute reticulocyte count (106/μL)† | 0.26 (∼0.15-0.34) | 0.21 (∼0.17-0.28) | 146.43 (0.01, 2644816) | .317 |
| WBC (103/μL)‡ | 12.40 (∼9.90-16.45) | 10.60 (∼6.90-14.20) | 1.03 (0.94, 1.12) | .517 |
| ANC ((/μL)§ | 7400 (∼5800-8500) | 5748 (∼2800-8200) | 1.01 (0.88, 1.16) | .869 |
| LDH (unit/L) | 495 (∼409-653) | 460 (∼367-544) | 1.29 (0.94, 1.79) | .118 |
| Total bilirubin (mg/dL) | 3.50 (∼1.50-5.50) | 2.80 (∼1.60-3.80) | 1.01 (0.73, 1.40) | .951 |
Categorical variables summarized as n (%). Continuous variables summarized as median (IQR, from Quartile 1 to Quartile 3). Indicated in bold, P < 0.05 is considered significant.
The analyses included transfusions (events) up to 7 days before all newly identified alloantibodies. Because antibody-positive transfusions usually occurred at a later time than antibody-negative transfusions for an individual patient (OR based transfusion events, 1.20; 95% CI, 1.02-1.41; P = .028), the association analyses were adjusted for patient age at the time of transfusions.
Exclude absolute reticulocyte counts during aplastic crisis.
The maximum WBC counts 7 days before and after the indicated transfused unit per transfusion event.
OR for ANC was based on a 1000-unit increase. The ORs for the remaining laboratory results were based on a 1-unit increase.